# Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

> **NCT04195243** · PHASE3 · UNKNOWN · sponsor: **Centro Universitario de Ciencias de la Salud, Mexico** · enrollment: 24 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin Pill
- **DRUG:** Empagliflozin Pill
- **DRUG:** Placebo pill

## Key facts

- **NCT ID:** NCT04195243
- **Lead sponsor:** Centro Universitario de Ciencias de la Salud, Mexico
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-02
- **Primary completion:** 2020-06-29
- **Final completion:** 2020-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2019-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04195243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04195243, "Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04195243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*